Literature DB >> 26178158

PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas.

Carlos L Morais1, Mehsati Herawi1, Antoun Toubaji1, Roula Albadine1, Jessica Hicks1, George J Netto1,2,3, Angelo M De Marzo1,2,3, Jonathan I Epstein1,2,3, Tamara L Lotan1,2.   

Abstract

BACKGROUND: Prostatic ductal adenocarcinoma is an unusual and aggressive morphologic subtype of prostate cancer. PTEN gene deletion and ERG gene rearrangement are among the most common genomic changes in acinar prostate cancers. Though ductal adenocarcinoma most commonly occurs with synchronous usual-type acinar adenocarcinoma, little is known about the molecular phenotype of these mixed tumors.
METHODS: We used genetically validated immunohistochemistry (IHC) assays to assess PTEN and ERG status in a group of 37 surgically treated ductal adenocarcinomas and 18 synchronous acinar adenocarcinomas where we have previously reported ERG gene rearrangement status by fluorescence in situ hybridization (FISH). A group of 34 stage and grade-matched pure acinar adenocarcinoma cases was studied as a control.
RESULTS: ERG IHC was highly concordant with ERG FISH results, with 100% (36/36) concordance among ductal adenocarcinomas and 91% (31/34) concordance among 34 pure acinar carcinomas. Similar to previous FISH results, ERG expression by IHC was significantly less common among ductal adenocarcinomas (11% or 4/37) and their synchronous acinar tumors (6% or 1/18) compared to matched pure acinar adenocarcinoma cases (50% or 17/34; P = 0.0005 and 0.002, respectively). PTEN loss by IHC was also less common among ductal adenocarcinomas (18% or 6/34) and their synchronous acinar tumors (22% or 4/18) compared to matched pure acinar carcinomas (50% or 17/34; P = 0.01 and 0.08, respectively). As expected, PTEN loss was enriched among ERG positive compared to ERG-negative tumors in the pure acinar tumor control group (2.5-fold enrichment; P = 0.04) however this was not observed among the ductal adenocarcinomas (1.5 fold enrichment; P = NS). Of ductal adenocarcinomas with an evaluable synchronous acinar component, ERG status was concordant in 94% (17/18) and PTEN status was concordant in 94% (16/17).
CONCLUSIONS: Based on PTEN and ERG, ductal adenocarcinomas and their concurrent acinar carcinomas may be clonally related in some cases and show important molecular differences from pure acinar carcinoma.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  ERG; PTEN; ductal adenocarcinoma; endometrioid; immunohistochemistry; prostatic adenocarcinoma

Mesh:

Substances:

Year:  2015        PMID: 26178158      PMCID: PMC4537350          DOI: 10.1002/pros.23042

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  63 in total

1.  Incidence and outcomes of ductal carcinoma of the prostate in the USA: analysis of data from the Surveillance, Epidemiology, and End Results program.

Authors:  Joshua J Meeks; Lee C Zhao; John Cashy; Shilajit Kundu
Journal:  BJU Int       Date:  2011-08-24       Impact factor: 5.588

2.  Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer.

Authors:  Tarek A Bismar; Maisa Yoshimoto; Qiuli Duan; Shuhong Liu; Kanishka Sircar; Jeremy A Squire
Journal:  Histopathology       Date:  2012-01-19       Impact factor: 5.087

3.  Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.

Authors:  Himisha Beltran; David S Rickman; Kyung Park; Sung Suk Chae; Andrea Sboner; Theresa Y MacDonald; Yuwei Wang; Karen L Sheikh; Stéphane Terry; Scott T Tagawa; Rajiv Dhir; Joel B Nelson; Alexandre de la Taille; Yves Allory; Mark B Gerstein; Sven Perner; Kenneth J Pienta; Arul M Chinnaiyan; Yuzhuo Wang; Colin C Collins; Martin E Gleave; Francesca Demichelis; David M Nanus; Mark A Rubin
Journal:  Cancer Discov       Date:  2011-11       Impact factor: 39.397

4.  Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.

Authors:  Antje Krohn; Tobias Diedler; Lia Burkhardt; Pascale-Sophie Mayer; Colin De Silva; Marie Meyer-Kornblum; Darja Kötschau; Pierre Tennstedt; Joseph Huang; Clarissa Gerhäuser; Malte Mader; Stefan Kurtz; Hüseyin Sirma; Fred Saad; Thomas Steuber; Markus Graefen; Christoph Plass; Guido Sauter; Ronald Simon; Sarah Minner; Thorsten Schlomm
Journal:  Am J Pathol       Date:  2012-06-13       Impact factor: 4.307

5.  Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas.

Authors:  Antoun Toubaji; Roula Albadine; Alan K Meeker; William B Isaacs; Tamara Lotan; Michael C Haffner; Alcides Chaux; Jonathan I Epstein; Misop Han; Patrick C Walsh; Alan W Partin; Angelo M De Marzo; Elizabeth A Platz; George J Netto
Journal:  Mod Pathol       Date:  2011-07-08       Impact factor: 7.842

6.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.

Authors:  Christopher E Barbieri; Sylvan C Baca; Michael S Lawrence; Francesca Demichelis; Mirjam Blattner; Jean-Philippe Theurillat; Thomas A White; Petar Stojanov; Eliezer Van Allen; Nicolas Stransky; Elizabeth Nickerson; Sung-Suk Chae; Gunther Boysen; Daniel Auclair; Robert C Onofrio; Kyung Park; Naoki Kitabayashi; Theresa Y MacDonald; Karen Sheikh; Terry Vuong; Candace Guiducci; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Gordon Saksena; Douglas Voet; Wasay M Hussain; Alex H Ramos; Wendy Winckler; Michelle C Redman; Kristin Ardlie; Ashutosh K Tewari; Juan Miguel Mosquera; Niels Rupp; Peter J Wild; Holger Moch; Colm Morrissey; Peter S Nelson; Philip W Kantoff; Stacey B Gabriel; Todd R Golub; Matthew Meyerson; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway
Journal:  Nat Genet       Date:  2012-05-20       Impact factor: 38.330

7.  Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer.

Authors:  Alison H M Reid; Gerhardt Attard; Daniel Brewer; Susana Miranda; Ruth Riisnaes; Jeremy Clark; Lucy Hylands; Sue Merson; Roy Vergis; Charles Jameson; Søren Høyer; Karina Dalsgaard Sørenson; Michael Borre; Chris Jones; Johann S de Bono; Colin S Cooper
Journal:  Mod Pathol       Date:  2012-03-30       Impact factor: 7.842

8.  PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients.

Authors:  Tamara L Lotan; Bora Gurel; Siobhan Sutcliffe; David Esopi; Wennuan Liu; Jianfeng Xu; Jessica L Hicks; Ben H Park; Elizabeth Humphreys; Alan W Partin; Misop Han; George J Netto; William B Isaacs; Angelo M De Marzo
Journal:  Clin Cancer Res       Date:  2011-08-30       Impact factor: 12.531

9.  PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer.

Authors:  Kanishka Sircar; Maisa Yoshimoto; Federico A Monzon; Ismael H Koumakpayi; Ruth L Katz; Abha Khanna; Karla Alvarez; Guanyong Chen; Andrew D Darnel; Armen G Aprikian; Fred Saad; Tarek A Bismar; Jeremy A Squire
Journal:  J Pathol       Date:  2009-08       Impact factor: 7.996

10.  The mutational landscape of lethal castration-resistant prostate cancer.

Authors:  Catherine S Grasso; Yi-Mi Wu; Dan R Robinson; Xuhong Cao; Saravana M Dhanasekaran; Amjad P Khan; Michael J Quist; Xiaojun Jing; Robert J Lonigro; J Chad Brenner; Irfan A Asangani; Bushra Ateeq; Sang Y Chun; Javed Siddiqui; Lee Sam; Matt Anstett; Rohit Mehra; John R Prensner; Nallasivam Palanisamy; Gregory A Ryslik; Fabio Vandin; Benjamin J Raphael; Lakshmi P Kunju; Daniel R Rhodes; Kenneth J Pienta; Arul M Chinnaiyan; Scott A Tomlins
Journal:  Nature       Date:  2012-07-12       Impact factor: 49.962

View more
  15 in total

Review 1.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

Review 2.  The pathology of unusual subtypes of prostate cancer.

Authors:  Jing Li; Zhe Wang
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

3.  Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate.

Authors:  Christopher M Heaphy; Michael C Haffner; Mindy K Graham; David Lim; Christine Davis; Eva Corey; Jonathan I Epstein; Mario A Eisenberger; Hao Wang; Angelo M De Marzo; Alan K Meeker; Tamara L Lotan
Journal:  Hum Pathol       Date:  2020-05-07       Impact factor: 3.466

4.  Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer.

Authors:  Marc Gillard; Justin Lack; Andrea Pontier; Divya Gandla; David Hatcher; Adam G Sowalsky; Jose Rodriguez-Nieves; Donald Vander Griend; Gladell Paner; David VanderWeele
Journal:  Eur Urol Focus       Date:  2017-12-08

Review 5.  Cribriform Patterned Lesions in the Prostate Gland with Emphasis on Differential Diagnosis and Clinical Significance.

Authors:  Maria Destouni; Andreas C Lazaris; Vasiliki Tzelepi
Journal:  Cancers (Basel)       Date:  2022-06-21       Impact factor: 6.575

Review 6.  Optimizing the diagnosis and management of ductal prostate cancer.

Authors:  Weranja Ranasinghe; Daniel D Shapiro; Miao Zhang; Tharakeswara Bathala; Nora Navone; Timothy C Thompson; Bradley Broom; Ana Aparicio; Shi-Ming Tu; Chad Tang; John W Davis; Louis Pisters; Brian F Chapin
Journal:  Nat Rev Urol       Date:  2021-04-06       Impact factor: 14.432

7.  Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.

Authors:  Harsimar Kaur; Iryna Samarska; Jiayun Lu; Farzana Faisal; Benjamin L Maughan; Sanjana Murali; Kaushal Asrani; Mohamed Alshalalfa; Emmanuel S Antonarakis; Jonathan I Epstein; Corinne E Joshu; Edward M Schaeffer; Juan Miguel Mosquera; Tamara L Lotan
Journal:  Prostate       Date:  2020-07-10       Impact factor: 4.012

8.  Diverse Immunoprofile of Ductal Adenocarcinoma of the Prostate with an Emphasis on the Prognostic Factors.

Authors:  Se Un Jeong; Anuja Kashikar Kekatpure; Ja-Min Park; Minkyu Han; Hee Sang Hwang; Hui Jeong Jeong; Heounjeong Go; Yong Mee Cho
Journal:  J Pathol Transl Med       Date:  2017-08-09

9.  PIN-like ductal carcinoma of the prostate has frequent activating RAS/RAF mutations.

Authors:  Harsimar B Kaur; Daniela C Salles; Adina Paulk; Jonathan I Epstein; James R Eshleman; Tamara L Lotan
Journal:  Histopathology       Date:  2020-09-24       Impact factor: 5.087

10.  Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate.

Authors:  Michael T Schweizer; Heather H Cheng; Maria S Tretiakova; Funda Vakar-Lopez; Nola Klemfuss; Eric Q Konnick; Elahe A Mostaghel; Peter S Nelson; Evan Y Yu; Bruce Montgomery; Lawrence D True; Colin C Pritchard
Journal:  Oncotarget       Date:  2016-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.